Evidence map›Paper›PMID 40594740›Full record

ArticleScientific reports2025

LncRNA TMPO-AS1 facilitates cervical cancer cell tumorigenesis and ferroptosis resistance via interaction with LCN2.

Ying Ju, Xu Liu, Jintong Na, Jian He, Liangliang Wu, Zhuoran Wang, Chunxiu Peng, Yuan Liao, Zhiyong Zhang

Abstract read
PubMed Full text at PMC Publisher
In one paragraph

Article in Scientific reports, 2025. The graph could read no effect estimate from its abstract, so it casts no vote on the map. Cited by 4 papers.

0numbers the graph read from it
0cells of the map it votes in
4citing papers in PubMed
–field-weighted citation impact
1 · What the graph read from it

What it found

Each row is one number read from the abstract, on the scale the paper reported it, with its interval. Left of the dashed line favours the treatment, right favours the comparator. Under each row is the sentence it came from. New to these charts? A ten-minute tutorial.

The abstract states no effect estimate the extractor could read, or names no intervention and outcome on the map, so this paper lights no cell and moves no belief. It is still indexed, cited and linked below.

2 · The registry

The trial behind it

Trials whose registry record cites this paper, or whose number appears in the abstract. A trial that started after this paper was published is citing it as background, not reporting it.

Neither the registry nor the abstract names a trial number. If this is a trial report, that itself is worth knowing.

3 · Its place in the literature

Who cites it

4 citing papers in PubMed.

  1. Therapy resistance-related ncRNAs in cervical cancer: biomarkers and therapeutic targets.Daru : journal of Faculty of Pharmacy, Tehran University of Medical Sciences · 2026
    Review
  2. Review
  3. Review
  4. Review
4 · The record

Corrections and comments

PubMed lists nothing against this paper. Absence here is not a guarantee, only a check that was made.

5 · Who and what money

Authors and funding

9 authors.

Ying Ju *State Key Laboratory of Targeting Oncology, National Center for International Research of Bio-targeting Theranostics, Guangxi Key Laboratory of Bio-targeting Theranostics, Collaborative Innovation Center for Targeting Tumor Diagnosis and Therapy, Guangxi Medical University, Nanning, 530021, Guangxi, China.
Xu Liu *Department of Anesthesia and Perioperative Medicine, The First Affiliated Hospital of Xinxiang Medical University, Xinxiang, 453003, China.
Jintong Na *State Key Laboratory of Targeting Oncology, National Center for International Research of Bio-targeting Theranostics, Guangxi Key Laboratory of Bio-targeting Theranostics, Collaborative Innovation Center for Targeting Tumor Diagnosis and Therapy, Guangxi Medical University, Nanning, 530021, Guangxi, China.
Jian HeState Key Laboratory of Targeting Oncology, National Center for International Research of Bio-targeting Theranostics, Guangxi Key Laboratory of Bio-targeting Theranostics, Collaborative Innovation Center for Targeting Tumor Diagnosis and Therapy, Guangxi Medical University, Nanning, 530021, Guangxi, China.
Liangliang WuState Key Laboratory of Targeting Oncology, National Center for International Research of Bio-targeting Theranostics, Guangxi Key Laboratory of Bio-targeting Theranostics, Collaborative Innovation Center for Targeting Tumor Diagnosis and Therapy, Guangxi Medical University, Nanning, 530021, Guangxi, China.
Zhuoran WangDepartment of Clinical Medicine, First Clinical Medical College, Anhui Medical University, Hefei, 230032, China.
Chunxiu PengState Key Laboratory of Targeting Oncology, National Center for International Research of Bio-targeting Theranostics, Guangxi Key Laboratory of Bio-targeting Theranostics, Collaborative Innovation Center for Targeting Tumor Diagnosis and Therapy, Guangxi Medical University, Nanning, 530021, Guangxi, China.
Yuan LiaoState Key Laboratory of Targeting Oncology, National Center for International Research of Bio-targeting Theranostics, Guangxi Key Laboratory of Bio-targeting Theranostics, Collaborative Innovation Center for Targeting Tumor Diagnosis and Therapy, Guangxi Medical University, Nanning, 530021, Guangxi, China. liaoyuan2024@163.com.
Zhiyong ZhangState Key Laboratory of Targeting Oncology, National Center for International Research of Bio-targeting Theranostics, Guangxi Key Laboratory of Bio-targeting Theranostics, Collaborative Innovation Center for Targeting Tumor Diagnosis and Therapy, Guangxi Medical University, Nanning, 530021, Guangxi, China. zhiyongzhang@yahoo.com.

Funding

he National Natural Science Foundation of China 82073373the Scientific and Technological Innovation Major Base of Guangxi 2022-36-Z05
6 · The paper itself

Abstract

Ferroptosis, characterized by iron accumulation and lipid peroxidation, has demonstrated anti-tumor properties in multiple malignancies. Long non-coding RNAs play a crucial role in the tumorigenesis and progression of cervical squamous cell cancer; however, the mechanisms underlying the actions of many lncRNAs in ferroptosis remain elusive. Here, the expression level of LICN-TMPO-AS1 in CESC was detected using quantitative real-time polymerase chain reaction. Loss- and gain-of-function experiments with TMPO-AS1 were performed using the CCK-8 assay, transwell assays, clone formation assays, and xenograft models. The relationship between TMPO-AS1, Lipocalin 2, and SFPQ were identified and validated by RNA pull-down/mass spectrometry, co-immunoprecipitation, RNA immunoprecipitation (RIP) assay and western blotting. We found that TMPO-AS1 expression was frequently upregulated in CESC tissues and cells and was strongly associated with poor prognosis. TMPO-AS1 decreased the lipid reactive oxygen species, intracellular Fe

Indexed as

CarcinogenesisFerroptosisLipocalin-2RNA, Long NoncodingUterine Cervical NeoplasmsAnimalsCell Line, TumorFemaleGene Expression Regulation, NeoplasticHumansMiceMice, NudePTB-Associated Splicing FactorReactive Oxygen SpeciesLCN2 protein, humanLipocalin-2PTB-Associated Splicing FactorReactive Oxygen SpeciesRNA, Long NoncodingCervical squamous cell carcinomaFerroptosisLCN2ProliferationTMPO-AS1

Identifiers

PMID40594740
PMCPMC12219768

What OpenQuestion holds

Textmetadata
LicenceCC BY-NC-ND
Read underepoch 390

Registered trials

None linked

Read under generation 80e0d062 · epoch 390. Bibliography from PubMed, PubMed Central and OpenAlex; grants from NIH RePORTER; trial links from ClinicalTrials.gov; estimates, votes and beliefs from the OpenQuestion graph.